Cipla receives 6 observations from USFDA for Goa facility

Further to United States Food and Drug Administration (USFDA) inspection at Cipla Ltd's Goa manufacturing facility in September 2019 and the warning letter received in February 2020, the Goa plant recently underwent a USFDA inspection from 16th - 26th August 2022.

On conclusion of the inspection, the Company has now received 6 observations with some referencing to the observations made during the September 2019 inspection. There are no data integrity (DI) observations. The Company will work closely with the USFDA and is committed to address these within the stipulated time.

Shares of Cipla Limited was last trading in BSE at Rs. 1020.25 as compared to the previous close of Rs. 1025.45. The total number of shares traded during the day was 12031 in over 1072 trades.

The stock hit an intraday high of Rs. 1035.40 and intraday low of 1018.60. The net turnover during the day was Rs. 12347489.00.

Source : Equity Bulls

Keywords

Cipla INE059A01026 USFDA Inspection Goa ManufacturingFacility 6Observations